NRx Pharmaceuticals reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, on the future of the BriLife™ Covid-19 Investigational Vaccine.
NRx Pharmaceuticals today announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options to purchase up to an aggregate of 7,824,727 shares of common stock.
NRx Pharmaceuticals today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing antibody against the Omicron variant of the SARS-CoV-2 virus.
At this week’s 2022 H.C. Wainwright BioConnect Virtual Conference, NRx identified the plans to move forward with a vanguard trial of the BriLife investigational vaccine for COVID-19 as a heterologous booster for those already vaccinated with mRNA vaccines.
NRx Pharmaceuticals (Nasdaq: NRXP) filed a lawsuit on Monday against Relief Therapeutics (SIX: RLF,OTCQB: RLFTF, RLFTY), its former collaboration partner, in New York State Supreme Court.
NRx Pharmaceuticals announced that Nasdaq has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective December 20, 2021. The NBI is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.
